Skip to main content
Top
Published in: Intensive Care Medicine 9/2016

Open Access 01-09-2016 | Systematic Review

Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis

Authors: Geert Koster, Hanneke J. Bekema, Jørn Wetterslev, Christian Gluud, Frederik Keus, Iwan C. C. van der Horst

Published in: Intensive Care Medicine | Issue 9/2016

Login to get access

Abstract

Introduction

Milrinone is an inotrope widely used for treatment of cardiac failure. Because previous meta-analyses had methodological flaws, we decided to conduct a systematic review of the effect of milrinone in critically ill adult patients with cardiac dysfunction.

Methods

This systematic review was performed according to The Cochrane Handbook for Systematic Reviews of Interventions. Searches were conducted until November 2015. Patients with cardiac dysfunction were included. The primary outcome was serious adverse events (SAE) including mortality at maximum follow-up. The risk of bias was evaluated and trial sequential analyses were conducted. The quality of evidence was assessed by the Grading of Recommendations Assessment, Development and Evaluation criteria.

Results

A total of 31 randomised clinical trials fulfilled the inclusion criteria, of which 16 provided data for our analyses. All trials were at high risk of bias, and none reported the primary composite outcome SAE. Fourteen trials with 1611 randomised patients reported mortality data at maximum follow-up (RR 0.96; 95% confidence interval 0.76–1.21). Milrinone did not significantly affect other patient-centred outcomes. All analyses displayed statistical and/or clinical heterogeneity of patients, interventions, comparators, outcomes, and/or settings and all featured missing data.

Discussion

The current evidence on the use of milrinone in critically ill adult patients with cardiac dysfunction suffers from considerable risks of both bias and random error and demonstrates no benefits. The use of milrinone for the treatment of critically ill patients with cardiac dysfunction can be neither recommended nor refuted. Future randomised clinical trials need to be sufficiently large and designed to have low risk of bias.
Appendix
Available only for authorised users
Literature
1.
go back to reference McMurray JJV, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847. doi:10.1093/eurheartj/ehs104 CrossRefPubMed McMurray JJV, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847. doi:10.​1093/​eurheartj/​ehs104 CrossRefPubMed
3.
go back to reference Tang X, Liu P, Li R et al (2015) Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 117:186–194. doi:10.1111/bcpt.12385 CrossRefPubMed Tang X, Liu P, Li R et al (2015) Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 117:186–194. doi:10.​1111/​bcpt.​12385 CrossRefPubMed
7.
go back to reference Gluud C, Nikolova D, Klingenber SL et al (2015) Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2015, issue 4. Art. No.:LIVER Gluud C, Nikolova D, Klingenber SL et al (2015) Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2015, issue 4. Art. No.:LIVER
8.
go back to reference Brok J, Thorlund K, Wetterslev J, Gluud C (2009) Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 38:287–298. doi:10.1093/ije/dyn188 CrossRefPubMed Brok J, Thorlund K, Wetterslev J, Gluud C (2009) Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 38:287–298. doi:10.​1093/​ije/​dyn188 CrossRefPubMed
11.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, For the PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. doi:10.1136/bmj.b2535 Moher D, Liberati A, Tetzlaff J, Altman DG, For the PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. doi:10.​1136/​bmj.​b2535
13.
go back to reference Rao V, Ivanov J, Weisel RD et al (1996) Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg 112:38–51CrossRefPubMed Rao V, Ivanov J, Weisel RD et al (1996) Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg 112:38–51CrossRefPubMed
14.
go back to reference ICH Harmonised Tripartite Guideline (1995) Clinical safety data management: definitions and standards for expedited reporting. Fed Regist 60:11284–11287 ICH Harmonised Tripartite Guideline (1995) Clinical safety data management: definitions and standards for expedited reporting. Fed Regist 60:11284–11287
16.
go back to reference Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408–412CrossRefPubMed Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408–412CrossRefPubMed
17.
go back to reference Moher D, Jadad AR, Tugwell P (1996) Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 12:195–208CrossRefPubMed Moher D, Jadad AR, Tugwell P (1996) Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 12:195–208CrossRefPubMed
18.
go back to reference Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982–989CrossRefPubMed Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982–989CrossRefPubMed
19.
go back to reference Savović J, Jones HE, Altman DG et al (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157:429–438CrossRefPubMed Savović J, Jones HE, Altman DG et al (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157:429–438CrossRefPubMed
22.
go back to reference The Cochrane Collaboration (2014) Review Manager (RevMan) [Computer Program] Version 5.3 Copenhagen. The Nordic Cochrane Centre The Cochrane Collaboration (2014) Review Manager (RevMan) [Computer Program] Version 5.3 Copenhagen. The Nordic Cochrane Centre
24.
go back to reference Zhang J, Yu KF (1998) What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280:1690–1691CrossRefPubMed Zhang J, Yu KF (1998) What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280:1690–1691CrossRefPubMed
25.
go back to reference Demets DL (1987) Methods for combining randomized clinical trials: strengths and limitations. Stat Med 6:341–350CrossRefPubMed Demets DL (1987) Methods for combining randomized clinical trials: strengths and limitations. Stat Med 6:341–350CrossRefPubMed
26.
28.
go back to reference Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
30.
go back to reference Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20:641–654CrossRef Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20:641–654CrossRef
31.
go back to reference Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61:64–75CrossRefPubMed Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61:64–75CrossRefPubMed
32.
go back to reference Wetterslev J, Engstrøm J, Gluud C, Thorlund K (2012) Trial sequential analysis: methods and software for cumulative meta-analyses. In: Chandl J, Clarke M, Higgins J (eds) Cochrane methods, Cochrane DB Syst Rev Suppl 1, pp 1–56 Wetterslev J, Engstrøm J, Gluud C, Thorlund K (2012) Trial sequential analysis: methods and software for cumulative meta-analyses. In: Chandl J, Clarke M, Higgins J (eds) Cochrane methods, Cochrane DB Syst Rev Suppl 1, pp 1–56
33.
go back to reference Pogue JM, Yusuf S (1997) Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 18:580–593 (discussion 661–6)CrossRefPubMed Pogue JM, Yusuf S (1997) Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 18:580–593 (discussion 661–6)CrossRefPubMed
35.
go back to reference Pang Z, Zhao W (2011) Milrinone in treatment of patients with cardiac shock following acute myocardial infarction. J Clin Med Pr 15:82–83 Pang Z, Zhao W (2011) Milrinone in treatment of patients with cardiac shock following acute myocardial infarction. J Clin Med Pr 15:82–83
36.
go back to reference Yang G, Han Y, Tong M, Deng J (2007) Milrinone in treatment of patients with acute myocardial infarction and acute left heart failure. Chin Heart J 19:454–456 Yang G, Han Y, Tong M, Deng J (2007) Milrinone in treatment of patients with acute myocardial infarction and acute left heart failure. Chin Heart J 19:454–456
37.
go back to reference Tang X, Li R, Jing Q et al (2012) Observation on the clinical efficacy of milrinone in the treatment of heart failure patients with acute myocardial infarction. J Clin Med Pr 16:163–165 Tang X, Li R, Jing Q et al (2012) Observation on the clinical efficacy of milrinone in the treatment of heart failure patients with acute myocardial infarction. J Clin Med Pr 16:163–165
38.
go back to reference Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A (2001) Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth 15:306–315. doi:10.1053/jcan.2001.23274 CrossRef Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A (2001) Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth 15:306–315. doi:10.​1053/​jcan.​2001.​23274 CrossRef
39.
40.
go back to reference Aranda JM, Schofield RS, Pauly DF et al (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 145:324–329. doi:10.1067/mhj.2003.50 CrossRefPubMed Aranda JM, Schofield RS, Pauly DF et al (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 145:324–329. doi:10.​1067/​mhj.​2003.​50 CrossRefPubMed
42.
43.
go back to reference Brackbill ML, Stam MD, Schuller-Williams RV, Dhavle AA (2007) Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients. Ann Pharmacother 41:427–432. doi:10.1345/aph.1H500 CrossRefPubMed Brackbill ML, Stam MD, Schuller-Williams RV, Dhavle AA (2007) Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients. Ann Pharmacother 41:427–432. doi:10.​1345/​aph.​1H500 CrossRefPubMed
44.
go back to reference Cuffe MS, Califf RM, Adams KF et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA 287:1541–1547CrossRefPubMed Cuffe MS, Califf RM, Adams KF et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA 287:1541–1547CrossRefPubMed
47.
go back to reference Hadadzadeh M, Hosseini SH, Mostafavi Pour Manshadi SM et al (2013) Effect of Milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Med Iran 51(10):681–686 Hadadzadeh M, Hosseini SH, Mostafavi Pour Manshadi SM et al (2013) Effect of Milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Med Iran 51(10):681–686
48.
go back to reference Jebeli M, Ghazinoor M, Mandegar MH et al (2010) Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: a randomized controlled trial. Cardiol J 17:73–78PubMed Jebeli M, Ghazinoor M, Mandegar MH et al (2010) Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: a randomized controlled trial. Cardiol J 17:73–78PubMed
49.
go back to reference Karlsberg RP, DeWood MA, DeMaria AN et al (1996) Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone–Dobutamine Study Group. Clin Cardiol 19:21–30CrossRefPubMed Karlsberg RP, DeWood MA, DeMaria AN et al (1996) Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone–Dobutamine Study Group. Clin Cardiol 19:21–30CrossRefPubMed
50.
go back to reference Siostrzonek P, Koreny M, Delle-Karth G et al (2000) Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand 44:403–409CrossRefPubMed Siostrzonek P, Koreny M, Delle-Karth G et al (2000) Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand 44:403–409CrossRefPubMed
51.
go back to reference Möllhoff T, Schmidt C, Van Aken H et al (2002) Myocardial ischaemia in patients with impaired left ventricular function undergoing coronary artery bypass grafting—milrinone versus nifedipin. Eur J Anaesthesiol 19:796–802PubMed Möllhoff T, Schmidt C, Van Aken H et al (2002) Myocardial ischaemia in patients with impaired left ventricular function undergoing coronary artery bypass grafting—milrinone versus nifedipin. Eur J Anaesthesiol 19:796–802PubMed
52.
53.
go back to reference Pogue J, Yusuf S (1998) Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351:47–52CrossRefPubMed Pogue J, Yusuf S (1998) Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351:47–52CrossRefPubMed
54.
go back to reference Imberger G, Gluud C, Boylan J, Wetterslev J (2015) Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesth Analg 121:1611–1622. doi:10.1213/ANE.0000000000000892 CrossRefPubMed Imberger G, Gluud C, Boylan J, Wetterslev J (2015) Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesth Analg 121:1611–1622. doi:10.​1213/​ANE.​0000000000000892​ CrossRefPubMed
56.
go back to reference Lamontagne F, Meade MO, Hébert PC et al (2016) Canadian critical care trials group. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med 42:542–550. doi:10.1007/s00134-016-4237-3 CrossRefPubMed Lamontagne F, Meade MO, Hébert PC et al (2016) Canadian critical care trials group. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med 42:542–550. doi:10.​1007/​s00134-016-4237-3 CrossRefPubMed
58.
go back to reference Koster G, Wetterslev J, Gluud C et al (2015) Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 41(2):203–221. doi:10.1007/s00134-014-3604-1 CrossRefPubMed Koster G, Wetterslev J, Gluud C et al (2015) Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 41(2):203–221. doi:10.​1007/​s00134-014-3604-1 CrossRefPubMed
Metadata
Title
Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
Authors
Geert Koster
Hanneke J. Bekema
Jørn Wetterslev
Christian Gluud
Frederik Keus
Iwan C. C. van der Horst
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 9/2016
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4449-6

Other articles of this Issue 9/2016

Intensive Care Medicine 9/2016 Go to the issue